๐ฐ Simulations Plus News
Page 3 - Simulations Plus News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Simulations Plus. Real-time updates on events, politics, business and more.
April 3, 2024
Companies Reporting Before The Bell • Acuity Brands (NYSE:AYI) is projected to report quarterly earnings at $3.25 per share on revenue of $907.75 million.
April 3, 2024
Total revenue of $18.3 million and diluted earnings per share of $0.20 Maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68 ...
April 3, 2024
Strong Revenue Growth and Dividend Declaration in Q2 Fiscal 2024
April 3, 2024
Simulations Plus, Inc. ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024....
April 2, 2024
Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $39.94, for a total value of $798,800.00. Following the transaction, the director now owns 3,600,195 shares in the company, valued at […]
March 13, 2024
Simulations Plus, Inc. , a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Shawn OโConnor, chief executive officer,...
February 15, 2024
Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use ...
February 8, 2024
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$33.35 With US$38.54...
February 6, 2024
Simulations Plus, Inc. , a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare...
January 30, 2024
New version delivers on FDA collaborations and user feedback for expansion of non-oral delivery route models ...